Overview

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Phase:
PHASE3
Details
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Treatments:
Topotecan